A Phase 3 interventional study of Melatonin and Placebo in Multidrug-Resistant Gram-Negative Bacterial Infections and Antimicrobial Resistance, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Ain Shams University · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates whether adding melatonin to standard colistin therapy improves outcomes in patients with multidrug-resistant (MDR) Gram-negative bacterial infections. These infections are difficult to treat and are associated with high morbidity and mortality, particularly in critically ill patients.
Colistin is often used as a last-line antibiotic for these infections; however, its effectiveness may be limited, and it is associated with side effects such as kidney injury. Melatonin, a naturally occurring hormone, has antioxidant, anti-inflammatory, and immune-modulating properties that may enhance the effectiveness of antibiotics and reduce treatment-related complications.
In this randomized, double-blind, placebo-controlled study, adult patients receiving colistin will be assigned to receive either melatonin or a placebo in addition to standard care. The study will assess whether melatonin improves oxidative stress, infection control, and clinical outcomes while maintaining safety.
Antimicrobial resistance is a major global health challenge, particularly among Gram-negative bacteria, which have developed resistance to multiple antibiotic classes, including last-line agents such as colistin. These infections are especially prevalent in intensive care units and are associated with poor clinical outcomes.
Given the limited development of new antibiotics, alternative strategies such as the use of adjunctive therapies are being explored. Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone known for its role in circadian rhythm regulation, but it also exhibits antioxidant, anti-inflammatory, and immunomodulatory effects. Emerging experimental evidence suggests that melatonin may enhance antibiotic activity and help overcome resistance mechanisms, including those affecting colistin.
This study is a prospective, randomized, double-blind, placebo-controlled clinical trial conducted in adult patients with confirmed MDR Gram-negative bacterial infections requiring intravenous colistin therapy in the intensive care setting.
Participants will be randomly assigned in a 1:1 ratio to receive either oral melatonin (60 mg once daily) or a matching placebo, initiated concurrently with colistin therapy. All patients will receive standard antimicrobial treatment and supportive care according to institutional protocols.
The primary objective is to evaluate the effect of adjunctive melatonin on oxidative stress, measured by changes in serum malondialdehyde (MDA) levels. Secondary objectives include assessment of microbiological eradication, clinical response, inflammatory markers, renal safety (including the incidence of acute kidney injury), and overall clinical outcomes such as length of stay.
This study aims to determine whether melatonin can serve as a safe and effective adjunctive therapy to improve outcomes and potentially restore the efficacy of colistin in the treatment of multidrug-resistant Gram-negative infections.
59 studies on the registry are indexed under Gram-Negative Bacterial Infections; 11 are open to participants now.
This study's planned enrollment of 70 is close to the median of 70 across 43 interventional studies indexed under Gram-Negative Bacterial Infections.
Browse Gram-Negative Bacterial Infections studies →Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of infection caused by multidrug-resistant Gram-negative bacteria based on microbiological culture and sensitivity testing
Exclusion Criteria:
Pregnancy or lactation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive oral melatonin 60 mg once daily, initiated concurrently with the administration of the colistin loading dose
Drug: Melatonin
Patients will receive matching placebo capsules following the same dosing schedule.
Other: Placebo
Patients will receive oral melatonin 60 mg once daily, initiated concurrently with the administration of the colistin loading dose
Patients will receive matching placebo capsules following the same dosing schedule.
Oxidative stress marker
serum malondialdehyde (MDA) levels
Time frame: day 7
microbiological eradication
Clearance of the baseline MDR Gram-negative pathogen, confirmed by negative follow-up culture
Time frame: Day 7
inflammatory response
C reactive protein will be measured
Time frame: Day 7
No study locations are listed for this record.
Plan to share: No
Start is estimated for Mar 2026; primary completion for Aug 2026, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin
Gram-Negative Bacterial Infections →